Earlier this month, Anadys Pharmaceuticals, Inc. (ANDS) announced the commencement of dosing in a 12- week phase II trial with ANA598 in hepatitis C patients. ANA 598 will be evaluated in combination with interferon-alpha and ribavirin (current standard of care) in the mid-stage study. The study is expected to provide important data at the end of this year and in the first two quarters of 2010. A total of 90 patients are planned to be enrolled in the study, with 30 patients receiving ANA598 and 15 receiving placebo at each dose level. The study would test 200 mg and 400 mg doses of the drug. In order to maximize early viral suppression, each patient would receive two 800 mg doses on the first day. The study would be conducted at various sites in the U.S. Chronic hepatitis C virus (HCV) affects approximately 3.2 million people ...

Yesterday, Anadys Pharmaceuticals Inc. (ANDS) started a 12-week phase II trial of its ANA598 for hepatitis C patients. ANA 598 will be evaluated in combination with interferon-alpha and ribavirin (current standard of care) in the mid-stage study. Data from the trial is expected to be released at the end of this year and in the first two quarters of 2010.

A total of 90 patients are planned to be enrolled in the study, with 30 patients receiving ANA598 and 15 receiving placebo at each dose level. The study would test 200 mg and 400 mg doses of the drug. In order to maximize early viral suppression, each patient would receive two 800 mg doses on the first day. The study would be conducted at various sites in the U.S.

Chronic hepatitis C virus (HCV) affects nearly 3.2 million people in the United States and about 170 million people

...

GenVec, Inc.

(Public, NASDAQ:GNVC)

StocksHaven Investments profiles a clinical stage biopharmaceutical company developing gene-based therapeutic drugs and vaccines. Its lead product candidate, TNFerade biologic (TNFerade), is being developed for use in the treatment of cancer, and is currently undergoing Phase III trials which are expected to be completed by Q1 2010. In addition to its therapeutic product development programs, GenVec is working with collaborators to develop new applications for its technology through its vaccine development programs. The Company is developing a vaccine in animal health against foot-and-mouth disease and preventative vaccines for malaria, human immunodeficiency virus (HIV), respiratory syncytial virus, and Herpes Simplex Virus Type 2 (HSV-2). Surrounded by cash infusions through grants, mutual and institutional investors, multi-purpose products with billion dollar market potential, and an already flowing revenue stream – GenVec is one company you shouldn’t pass by.

About

Genvec

...

DrStockPick.com Stock Report!

Monday August 24, 2009

**************************************************************

Residents of the Tri-State area now have a new alternative to costly traditional wireless service plans. MetroPCS Communications, Inc. (NYSE: PCS), the nation’s leading provider of unlimited, flat-rate, no signed contract wireless communications service, announces the expansion of its New York City area service to include Long Island, North Central New Jersey, White Plains and New Rochelle, N.Y., Stamford and Bridgeport, Conn. This expansion includes two MetroPCS company-owned retail stores, 50 authorized dealer locations and fifteen Best Buy stores. MetroPCS’ expansion will bring 250 jobs to the area. For more information on MetroPCS and coverage areas, please go to www.metropcs.com.

Shiner International,

...

Shares of Biotechnology company InterMune Inc (NASDAQ: ITMN) are up 35% after announcing a late-stage study of its investigational treatment for a potentially fatal lung disease met the main goal, even as another late-stage trial of the same drug failed. Investors were extremely pessimistic about the outcome of the study given that no drug succeeded in the disease before, Canaccord Adams analyst Adam Cutler said by phone. People now think that there is a chance of the drug getting approved, when many assumed it did not have much chance before today. ITMN 1 Year Chart...